WS Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

WS Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,000	Closed	-$8.77M	–	75
2019 Q2	$8.77M	Sell	100,000 -50,000	-33%	-$4.26M	0.57%	34
2019 Q1	$13.6M	Buy	+150,000	New	+$12.8M	0.82%	27
2018 Q4	–	Sell	-50,000	Closed	-$4.79M	–	87
2018 Q3	$4.79M	Sell	50,000 -330,000	-87%	-$32M	0.16%	61
2018 Q2	$36.2M	Buy	+380,000	New	+$34.9M	1.02%	23

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

WS Management's XBI Position: Q2 2026 in Review

WS Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 33% in Q2 2026, buying an estimated $6.76M and bringing the position to 200,000 shares worth $31.6M. The position accounts for 2.77% of the portfolio, ranked #11.

WS Management first reported a position in XBI in Q2 2022 and has held it in 17 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

WS Management held 200,000 shares of State Street SPDR S&P Biotech ETF worth $31.6M as of Q2 2026.
WS Management bought 50,000 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.76M.
State Street SPDR S&P Biotech ETF made up 2.77% of WS Management's portfolio in Q2 2026, its #11 holding.
WS Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 17 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on WS Management's 13F filing for Q2 2026, filed 14 Aug 2026.